Clinical features and survival analysis of 40 cases of anti-MDA5 antibody-positive dermatomyositis complicated with interstitial lung disease

Background Several studies have shown that patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5 antibody + DM) have an increased risk of developing rapid progression of interstitial lung disease (RPILD), which is associated with poor prognosis and high mortality. However, diagnosis a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis research & therapy Jg. 27; H. 1; S. 32 - 14
Hauptverfasser:	Zhao, Kaikai, Zhang, Juan, Kong, Qunyu, Zhang, Yong, Li, Cong, Huo, Kaikai, Fan, Na, Deng, Wenjing, Shi, Jie, Wang, Chunya, Li, Xueyi, Yang, Shuanying, Fang, Ping
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 13.02.2025 BioMed Central Ltd BMC
Schlagworte:	Adult Aged Anti-MDA5 antibody Antibodies Autoantibodies - blood Autoantibodies - immunology Biological products Care and treatment Complications and side effects Dermatomyositis Dermatomyositis - complications Dermatomyositis - immunology Dermatomyositis - mortality Development and progression Diagnosis Dosage and administration Event history analysis Female Ferritin Genetic aspects Health aspects Humans Immunosuppressive agents Interferon-Induced Helicase, IFIH1 - immunology Interstitial lung disease Lung diseases Lung diseases, Interstitial Lung Diseases, Interstitial - complications Lung Diseases, Interstitial - immunology Lung Diseases, Interstitial - mortality Male Medical research Medicine Medicine & Public Health Medicine, Experimental Methods Middle Aged Mortality Nomograms Orthopedics Prognosis Prognostic factors Retrospective Studies Rheumatology Risk Factors Survival Analysis Viral antibodies Japan Anti-MDA5 antibody Interstitial lung disease Prognostic factors Dermatomyositis
ISSN:	1478-6354, 1478-6362, 1478-6362
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!